Become Your 2.0 →
Book A Free Discovery CallAdvanced Oncologic Risk Screening™
Gain Greater Visibility Into Oncologic Risk Biology
Cancer remains one of the most significant health challenges of modern life. One of the greatest limitations in oncology is timing.
Advanced Oncologic Risk Screening™ is our physician-led screening pathway designed to help identify early biological signals associated with increased oncologic risk, supporting more intelligent, proactive health decision-making.
- Advanced Oncologic Risk Intelligence
- Early Biological Signal Detection
- Physician-Led Risk Stratification































what's included
Why Choose Advanced Oncologic Risk Screening
An advanced blood-based assessment designed to detect circulating tumour cells and support intelligent physician-led risk stratification across a broad range of solid tumour types.
your Pathway
Pricing & Packs
Choose the level of clinical insight and support that best aligns with your health goals.
WHY HUM2N?
Advanced Screening, Expert Interpretation
Advanced Oncologic Risk Screening™ sits within a physician-led precision medicine framework, with results interpreted in the wider context of individual risk factors and biomarker intelligence.
01
Wider Biological Risk Context
Results are interpreted alongside family history, age-related risk, inflammatory burden, metabolic dysfunction, insulin resistance and obesity-related risk.
02
Comprehensive Risk Assessment
Consideration includes hormonal contributors, smoking history, environmental exposure, symptom review and wider biomarker intelligence.
03
Physician-Led Risk Stratification
A positive result does not confirm cancer and a negative result does not completely exclude it. Its role is intelligent physician-led risk stratification.
04
Specialist Oncology Network
Where further evaluation is required, HUM2N can coordinate rapid onward investigation and specialist support through its wider expert care ecosystem.
Testimonials
Success Validated
HUM2N TEAM
Meet The Experts

Dr Mohammed Enayat
Founder, CEO - MBBS, BSc, MRCGP, PGDip, AFMCP

Dr Mark Menolascino
Certified Medicine Specialist & Functional Medicine Doctor

Dr Sonia Panchal
Consultant Rheumatologist & Functional Medicine Doctor

Dr Reamika West
GP & Functional Medicine Doctor
Frequently asked questions
What does Advanced Oncologic Risk Screening™ assess?
This assessment uses advanced blood-based technology designed to detect circulating tumour cells (CTCs). Their presence can act as an early biological signal suggesting elevated cancer risk—sometimes before conventional clinical presentation.
What cancers can this assessment screen for?
The screening capability extends across 70+ solid tumour types, including breast, prostate, colorectal, pancreatic, ovarian, lung, thyroid, kidney, bladder, melanoma, selected neuroendocrine tumours, CNS malignancies and other solid organ cancers.
Who is Advanced Oncologic Risk Screening™ for?
This assessment may be appropriate for individuals who want a more proactive approach to cancer risk visibility, have family history of malignancy, are focused on preventative longevity medicine, have concern around environmental toxic exposure or want advanced executive health screening.
Does a positive result mean I have cancer?
No. A positive result does not confirm cancer. A negative result does not completely exclude it. No responsible clinician should interpret this as a standalone diagnosis. Its role is intelligent physician-led risk stratification.
Does this replace conventional cancer screening?
No. Advanced Oncologic Risk Screening™ is not intended to diagnose cancer independently or replace conventional screening programmes, including mammography, colonoscopy, PSA, cervical screening or imaging. It is designed to support earlier biological visibility within physician-led preventative care.




.webp)

